<DOC>
	<DOCNO>NCT01787383</DOCNO>
	<brief_summary>The purpose trial evaluate safety simultaneous treatment regimen compare sequential treatment regimen two separate area AKs ( one locate face/scalp locate trunk/ extremity ) treat ingenol mebutate gel</brief_summary>
	<brief_title>A Simultaneous Treatment Regimen Compared Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015 % 0.05 % Two Areas With Actinic Keratosis Face/Scalp Trunk/Extremities</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Subjects must provide informed consent Subjects 4 8 clinically typical , visible discrete AKs within contiguous 25 cm2 treatment area face scalp Subjects 4 8 clinically typical , visible discrete AKs within contiguous 25 cm2 treatment area trunk extremity Subjects least 18 year age Female subject must either : 1 . Nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus ) , 2 . Childbearing potential , provide confirm negative urine pregnancy test prior trial treatment , rule pregnancy . Female subject childbearing potential must willing use effective contraception trial entry completion . Location select treatment area : periorbital skin within 5 cm incompletely heal wound within 10 cm suspect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) Prior treatment ingenol mebutate gel face/scalp trunk/extremities Lesions select treatment area : atypical clinical appearance ( and/or , recalcitrant disease History evidence skin condition trial indication would interfere evaluation trial medication Use cosmetic therapeutic product procedure could interfere assessment select treatment area Clinical diagnosis/history evidence medical condition would expose subject undue risk significant AE interfere assessment safety efficacy course trial , determine investigator 's clinical judgment . Anticipated need hospitalisation outpatient surgery first 15 day first trial medication application . Known sensitivity allergy ingredient ingenol mebutate gel Presence sunburn within select treatment area Current enrolment participation investigational clinical trial within 30 day entry trial Subjects previously randomise trial Female subject breastfeed In opinion investigator , subject unlikely comply Clinical Study Protocol Prohibited Therapies and/or Medications within 2 week prior Visit 1 : Cosmetic therapeutic procedure within 2 cm select treatment area Use topical keratolytic therapeutic product within 2 cm select treatment area Use topical medicate cream , ointment , lotion , gel , foam spray include topical steroid : within 2 cm select treatment area ; artificial tanner : within 5 cm select treatment area Prohibited Therapies and/or Medications : within 4 week prior Visit 1 : Treatment immunomodulators , cytotoxic drug interferon/interferon inducer Treatment systemic medication suppress immune system Treatment/therapy ultraviolet light A ( UVA ) ultraviolet light B ( UVB ) Prohibited Therapies and/or Medications within 8 week prior Visit 1 : Treatment 5fluorouracil ( 5FU ) , imiquimod , topical diclofenac sodium , photodynamic therapy within 2 cm select treatment area . Prohibited Therapies and/or Medications within 6 month prior Visit 1 : Use systemic retinoids biologic/monoclonal antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>Ingenol mebutate gel</keyword>
</DOC>